Literature DB >> 28925408

Liver volume and hepatic adiposity in childhood: relations to body growth and visceral fat.

R Malpique1,2, J Bassols3, A López-Bermejo3, M Diaz1,2, F Villarroya4,5, J Pavia6,7, A Congo6, F de Zegher8, L Ibáñez1,2.   

Abstract

BACKGROUND AND
OBJECTIVE: The sequence of prenatal growth restraint and postnatal catch-up growth may lead to hepato-visceral adiposity, insulin resistance and low-grade inflammation before the onset of puberty. In prepubertal children born appropriate for gestational age (AGA) or small for gestational age (SGA), we assessed potential relationships between the aforementioned sequence and liver volume. SUBJECTS/
METHODS: The study population consisted of 86 children (41 AGA and 45 SGA with catch-up growth; age (mean±s.e.m.), 8.5±0.1 years), recruited into two prospective longitudinal studies. Anthropometry, endocrine-metabolic variables and inflammatory and hepatic markers were assessed, along with liver volume, hepatic adiposity and abdominal fat partitioning (by magnetic resonance imaging).
RESULTS: AGA and SGA children differed in hepato-visceral adiposity, but had similar liver volumes. Boys had larger livers than girls, and higher sex hormone binding globulin and inflammation markers. Liver volume correlated with height Z-score, body mass index Z-score, HOMA-IR (homeostasis model assessment-insulin resistance) and with subcutaneous and visceral fat, but not with birth weight Z-score or with hepatic adiposity. Height, visceral fat, gender and HOMA-IR were major determinants of liver volume, together explaining 61% of its variance.
CONCLUSIONS: The trajectory from prenatal restraint, via postnatal catch-up, to hepato-visceral adiposity and insulin resistance does not appear to be detectably influenced by prepubertal alterations of liver volume. Further follow-up will disclose the potential role of liver volume in the pubertal segment of this trajectory, and whether the augmented fat content and visceral adiposity in SGA subjects is followed by the development of metabolic syndrome and hepatic dysfunction in adulthood.

Entities:  

Mesh:

Year:  2017        PMID: 28925408     DOI: 10.1038/ijo.2017.198

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  47 in total

1.  Hepatic left lobe volume is a sensitive index of metabolic improvement in obese women after gastric banding.

Authors:  M Giannetti; P Piaggi; G Ceccarini; S Mazzeo; G Querci; P Fierabracci; G Salvetti; G Galli; I Ricco; S Martinelli; C Di Salvo; M Anselmino; A Landi; P Vitti; A Pinchera; F Santini
Journal:  Int J Obes (Lond)       Date:  2011-12-06       Impact factor: 5.095

2.  Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding.

Authors:  Luca Busetto; Alberto Tregnaghi; Francesco De Marchi; Gianni Segato; Mirto Foletto; Giuseppe Sergi; Franco Favretti; Mario Lise; Giuliano Enzi
Journal:  Obes Res       Date:  2002-05

3.  The sequence of prenatal growth restraint and post-natal catch-up growth leads to a thicker intima-media and more pre-peritoneal and hepatic fat by age 3-6 years.

Authors:  G Sebastiani; M Díaz; J Bassols; G Aragonés; A López-Bermejo; F de Zegher; L Ibáñez
Journal:  Pediatr Obes       Date:  2015-07-01       Impact factor: 4.000

4.  Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.

Authors:  Z Permutt; T-A Le; M R Peterson; E Seki; D A Brenner; C Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2012-05-03       Impact factor: 8.171

5.  Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.

Authors:  S C Lin; E Heba; R Bettencourt; G Y Lin; M A Valasek; O Lunde; G Hamilton; C B Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2017-01-24       Impact factor: 8.171

6.  Visceral fat and liver fat are independent predictors of metabolic risk factors in men.

Authors:  Thanh-Binh Nguyen-Duy; Milton Z Nichaman; Timothy S Church; Steven N Blair; Robert Ross
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-01-28       Impact factor: 4.310

7.  Ultrasonographic evaluation of liver volume and the metabolic syndrome in obese women.

Authors:  F Santini; M Giannetti; S Mazzeo; P Fierabracci; G Scartabelli; A Marsili; R Valeriano; A Pucci; M Anselmino; V Zampa; P Vitti; A Pinchera
Journal:  J Endocrinol Invest       Date:  2007-02       Impact factor: 4.256

8.  Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects.

Authors:  Jukka Westerbacka; Maria Kolak; Tuula Kiviluoto; Perttu Arkkila; Jukka Sirén; Anders Hamsten; Rachel M Fisher; Hannele Yki-Järvinen
Journal:  Diabetes       Date:  2007-08-17       Impact factor: 9.461

9.  Nonalcoholic fatty liver disease in prepubertal children born small for gestational age: influence of rapid weight catch-up growth.

Authors:  Maria Felicia Faienza; Giacomina Brunetti; Annamaria Ventura; Mariangela D'Aniello; Tiziana Pepe; Paola Giordano; Mariantonietta Monteduro; Luciano Cavallo
Journal:  Horm Res Paediatr       Date:  2013-02-28       Impact factor: 2.852

10.  Cord Blood Adipokines and Lipids and Adolescent Nonalcoholic Fatty Liver Disease.

Authors:  Joy Simpson; Andrew D Smith; Abigail Fraser; Naveed Sattar; Mark Callaway; Robert S Lindsay; Debbie A Lawlor; Scott M Nelson
Journal:  J Clin Endocrinol Metab       Date:  2016-09-20       Impact factor: 5.958

View more
  1 in total

1.  Are body surface area based estimates of liver volume applicable to children with overweight or obesity? An in vivo validation study.

Authors:  Chelsea Hosey-Cojocari; Sherwin S Chan; Chance S Friesen; Amie Robinson; Veronica Williams; Erica Swanson; Daniel O'Toole; Jansynn Radford; Neil Mardis; Trevor N Johnson; J Steven Leeder; Valentina Shakhnovich
Journal:  Clin Transl Sci       Date:  2021-05-31       Impact factor: 4.689

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.